alteplase or tenecteplase
Phase 3Protein / enzyme
alteplase or tenecteplase is one of 43 small molecule programs targeting Ischemic stroke. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
119 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Tnkase
RochePhase 3
Ozempic
Novo NordiskPhase 3
Reminyl
WWim Janssens
Phase 3
Intravenous Thrombolysis
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
Butylphthalide
PPeking Union Medical College Hospital
Phase 3
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
Aggrastat
MMedicure
Phase 3
Zastaprazan
YYonsei University
Phase 3
Edaravone Dexborneol
SSimcere Pharmaceutical Co., Ltd
Phase 3
SGLT-2 Inhibitors
Novo NordiskPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ischemic stroke1 trial
Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC
Recruiting·—·N/A·NCT06241677·260 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for alteplase or tenecteplase. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company
- CChinese University of Hong Kong